Merck Serono bolsters BMS's Chinese Glucophage push
This article was originally published in Scrip
Executive Summary
Merck Serono is to join forces with Bristol-Myers Squibb to expand sales of the type 2 diabetes treatment Glucophage (metformin) in China. The US firm (which has US rights to the product) has been promoting the product in China since 1999, after licensing rights from Merck.